Table 1 Baseline characteristics of patients and tumours (n = 1004)
Characteristics | Number of cases (%) |
|---|---|
Age (years) | |
  ≤ 50 | 570 (56.8%) |
  >  50 | 434 (43.2%) |
Menstrual status | |
 Premenopausal | 336 (33.5%) |
 Perimenopausal | 391 (38.9%) |
 Postmenopausal | 277 (27.6%) |
Tumour size (cm) | |
  ≤ 2 | 92 (9.2%) |
 2–5 | 706 (70.3%) |
  >  5 | 206 (20.5%) |
Lymph node involvement | |
 N0 | 365 (36.4%) |
 N1 | 472 (47.0%) |
 N2–3 | 167 (16.6%) |
Clinical stage | |
 I | 38 (3.8%) |
 II | 702 (69.9%) |
 III | 264 (26.3%) |
Histological subtype | |
 Ductal | 970 (96.6%) |
 Lobular | 14 (1.4%) |
 Other | 16 (1.6%) |
 Unknown | 4 (0.4%) |
ER status | |
 Positive | 600 (59.8%) |
 Negative | 404 (40.2%) |
PR status | |
 Positive | 441 (43.9%) |
 Negative | 563 (56.1%) |
HER2 status | |
 Positive | 427 (42.5%) |
 Negative | 522 (52.0%) |
 Unknown | 55 (5.5%) |
Ki67 status (%) | |
  ≤ 14 | 266 (26.5%) |
 14–30 | 466 (46.4%) |
  > 30 | 272 (27.1%) |
Subtype | |
 HR (+) HER2 (−) | 361 (36.0%) |
 HR (+) HER2 (+) | 211 (21.0%) |
 HR (−) HER2 (+) | 222 (22.1%) |
 HR (−) HER2 (−) | 155 (15.4%) |
 Unknown | 55 (5.5%) |
Chemotherapy cycles | |
  < 4 | 18 (1.8) |
 4 | 918 (91.4) |
  > 4 | 68 (6.8) |
Responder | |
 pCR | 125 (12.5) |
 cCR | 73 (7.3) |
 PR | 484 (48.2) |
 SD | 301 (30.0) |
 PD | 21 (2.0) |